Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product includes EXPAREL, is a non-opioid local analgesic indicated for administration into the surgical site to produce postsurgical analgesia. EXPAREL combines bupivacaine with the DepoFoam to provide postsurgical pain control with a single intraoperative infiltration.


Type
Public
HQ
Parsippany-Troy Hills, US
Founded
2006
Size (employees)
503 (est)
Website
pacira.com
Pacira Pharmaceuticals was founded in 2006 and is headquartered in Parsippany-Troy Hills, US
Report incorrect company information

Pacira Pharmaceuticals Office Locations

Pacira Pharmaceuticals has offices in San Diego and Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
5 Sylvan Way
San Diego, US
10578 Science Center Dr, Suite 125
San Diego, US
11011 N Torrey Pines Rd
Show all (3)
Report incorrect company information

Pacira Pharmaceuticals Financials and Metrics

Pacira Pharmaceuticals Financials

Pacira Pharmaceuticals's revenue was reported to be $286.63 m in FY, 2017
USD

Revenue (Q1, 2018)

74.6 m

Gross profit (Q1, 2018)

51.7 m

Gross profit margin (Q1, 2018), %

69.3%

Net income (Q1, 2018)

(10.7 m)

EBIT (Q1, 2018)

(6.9 m)

Market capitalization (14-Jun-2018)

1.6 b

Closing share price (14-Jun-2018)

38.5

Cash (31-Mar-2018)

41.6 m
Pacira Pharmaceuticals's current market capitalization is $1.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

85.6 m197.7 m249 m276.4 m286.6 m

Revenue growth, %

131%26%11%

Cost of goods sold

54.8 m77.4 m71.8 m77.4 m87.9 m

Gross profit

30.8 m120.2 m177.2 m198.9 m198.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

23.3 m36.7 m47.2 m52 m58.3 m59.1 m62.2 m65.5 m69.6 m68.4 m69.3 m70.9 m74.6 m

Cost of goods sold

14.8 m18.1 m20 m20.4 m17.6 m18.9 m15.9 m20.3 m23.1 m43.2 m24.6 m23.8 m22.9 m

Gross profit

8.5 m18.5 m27.2 m31.7 m40.7 m40.2 m46.3 m45.2 m46.6 m25.2 m44.7 m47.1 m51.7 m

Gross profit Margin, %

36%51%58%61%70%68%74%69%67%37%65%66%69%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

12.5 m37.5 m57 m35.9 m54.1 m

Accounts Receivable

14.6 m22.4 m25.9 m29.9 m31.7 m

Inventories

15.6 m29.3 m6.1 m31.3 m41.4 m

Current Assets

106.8 m214.3 m252.6 m243.1 m391.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

3.4 m18.8 m108.2 m17.8 m40.9 m32.7 m30.5 m35 m25.3 m24.4 m109 m53.8 m41.6 m

Accounts Receivable

9.8 m16 m20.5 m20.5 m24.5 m24.3 m25.9 m25.9 m28.7 m26.8 m27.7 m27.5 m31.2 m

Inventories

15.6 m15.4 m19.2 m23.7 m36.3 m48.8 m56.1 m63.7 m60.9 m37.5 m30.3 m33.6 m40 m

Current Assets

111.7 m98.5 m208.9 m199.2 m248.6 m258 m235.4 m448 m451 m418.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(63.9 m)(13.7 m)1.9 m(13.7 m)(42.6 m)

Depreciation and Amortization

5.7 m

Inventories

(3.5 m)(14 m)(32 m)(10.1 m)

Accounts Payable

10.2 m14.3 m9.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(52 m)(11.5 m)(16.5 m)(19.5 m)1.3 m1.3 m4.4 m(3.9 m)(11.8 m)(34 m)(19.9 m)(39.6 m)(10.7 m)

Depreciation and Amortization

4 m2.6 m4.9 m

Inventories

(3.5 m)193 k(3.6 m)(8.1 m)(7 m)1.4 m

Accounts Payable

6.4 m(1.5 m)5.2 m10.2 m(4.3 m)5 m2 m(6.2 m)(8.7 m)106 k
USDY, 2018

Financial Leverage

2.2 x
Show all financial metrics
Report incorrect company information